Defining the safety and efficacy of liver-directed AAV gene therapy using a human liver tissue-equivalent platform.
This preclinical study evaluated liver-directed AAV gene therapy using human liver tissue equivalents (hLTEs) engineered to replicate native liver cell composition, physiology, and function, assessing transduction efficiency, cellular tropism, and genotoxicity across multiple AAV constructs. The hLTE platform demonstrated value for human-relevant safety assessment and provides critical mechanistic insights for developing safer and more effective liver-directed gene therapies for rare monogenic diseases.
This preclinical study evaluated liver-directed AAV gene therapy using human liver tissue equivalents (hLTEs) engineered to replicate native liver cell composition, physiology, and function, assessing transduction efficiency, cellular tropism, and genotoxicity across multiple AAV constructs. The hLTE platform demonstrated value for human-relevant safety assessment and provides critical mechanistic insights for developing safer and more effective liver-directed gene therapies for rare monogenic diseases.
What the study was
- Study design
- Not specified
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Molecular therapy. Advances
Why it surfaced
Relevant Rare diseases with high unmet need study (promising preliminary signal) meets standard-priority threshold.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.